Alteogen Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 157

Employees

  • Stock Symbol
  • 196170

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $127.90
  • (As of Wednesday Closing)

Alteogen General Information

Description

Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars through partnerships with pharmaceutical companies. It focuses on areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 62, Yuseong-daero 1628beon-gil, Yuseong-gu
  • Yuseong
  • Daejeon, 34054
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
KRX
Corporate Office
  • 62, Yuseong-daero 1628beon-gil, Yuseong-gu
  • Yuseong
  • Daejeon, 34054
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alteogen Stock Performance

As of 18-Nov-2026, Alteogen’s stock price is $127.90. Its current market cap is $8.89B with 69.5M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$127.90 $129.48 $111.66 - $297.06 $8.89B 69.5M 472K $1.90

Alteogen Financials Summary

As of 30-Jun-2026, Alteogen has a trailing 12-month revenue of $175M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 12,251,818 16,463,789 11,052,558 3,850,198
Revenue 175,030 151,678 75,382 73,825
EBITDA 151,568 118,039 23,686 (3,634)
Net Income 132,092 99,545 45,625 (2,579)
Total Assets 479,525 485,235 277,678 198,731
Total Debt 4,543 4,902 7,983 1,323
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alteogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alteogen‘s full profile, request access.

Request a free trial

Alteogen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion T
Drug Discovery
Daejeon, South Korea
157 As of 2025

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alteogen Competitors (1)

One of Alteogen’s competitors is Halozyme Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Halozyme Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 1 of 1 competitors. Get the full list »

Alteogen Patents

Alteogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026142345-A1 Stable liquid formulation of fusion protein having igg fc domain Pending 24-Dec-2024
WO-2026071755-A1 Use of subcutaneous injection formulation comprising hyaluronidase used in combination with antibody-drug conjugate, and method for treating disease by using same Pending 25-Sep-2024
WO-2025249934-A1 Pharmaceutical composition for subcutaneous injection, comprising growth hormone receptor antagonist and long-acting carrier Pending 29-May-2024
WO-2024248231-A1 Method for producing long-acting hormone receptor antagonists Inactive 01-Jun-2023
EP-4685232-A1 Novel hyaluronidase variants and pharmaceutical composition comprising same Pending 23-Mar-2023 C12N9/2434
To view Alteogen’s complete patent history, request access »

Alteogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alteogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alteogen‘s full profile, request access.

Request a free trial

Alteogen Investments & Acquisitions (4)

Alteogen’s most recent deal was a Early Stage VC with Thor Therapeutics. The deal was made on 30-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Thor Therapeutics 30-Oct-2026 Early Stage VC Drug Discovery
Altos Biologics 06-Oct-2026 Secondary Transaction - Private Biotechnology
Altos Biologics 22-May-2025 Merger/Acquisition Biotechnology
GS Platech (13198.13 Square Meters Land and Building in Daejeon, South Korea) 31-Mar-2015 Corporate Asset Purchase Buildings and Property
To view Alteogen’s complete investments and acquisitions history, request access »

Alteogen ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

33.53 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Alteogen’s complete esg history, request access »

Alteogen FAQs

  • When was Alteogen founded?

    Alteogen was founded in 2008.

  • Where is Alteogen headquartered?

    Alteogen is headquartered in Daejeon, South Korea.

  • What is the size of Alteogen?

    Alteogen has 157 total employees.

  • What industry is Alteogen in?

    Alteogen’s primary industry is Drug Discovery.

  • Is Alteogen a private or public company?

    Alteogen is a Public company.

  • What is Alteogen’s stock symbol?

    The ticker symbol for Alteogen is 196170.

  • What is the current stock price of Alteogen?

    As of 18-Nov-2026 the stock price of Alteogen is $127.90.

  • What is the current market cap of Alteogen?

    The current market capitalization of Alteogen is $8.89B.

  • What is Alteogen’s current revenue?

    The trailing twelve month revenue for Alteogen is $175M.

  • Who are Alteogen’s competitors?

    Halozyme Therapeutics is a competitor of Alteogen.

  • What is Alteogen’s annual earnings per share (EPS)?

    Alteogen’s EPS for 12 months was $1.90.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process